Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25896258 | 0.81 | HDAC3 (0.33) | — | |
| SCHEMBL25920184 | 0.80 | PRMT3 (0.31) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL20029362 | 0.79 | — | — | |
| SCHEMBL8686965 | 0.76 | PRMT3 (0.46) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL14865063 | 0.76 | PRMT3 (0.38) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL179678 | 0.73 | — | — | |
| SCHEMBL14518610 | 0.72 | PRMT3 (0.42) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL23730577 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL19924993 | 0.71 | PRMT3 (0.46) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL27467974 | 0.71 | PRMT3 (0.50) | PRMT3CARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4275677-A2 | DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND | Ascendis Pharma Bone Diseases A/S (DK) | 2023-11-15 | — | — | EP | disclosed |
| US-20230248836-A1 | Dosage Regimen for a Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-08-10 | — | — | US | disclosed |
| US-20230218722-A1 | PTH Compounds with Low Peak-To-Trough Ratios | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-07-13 | — | — | US | disclosed |
| WO-2020165087-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248836-A1 | Dosage Regimen for a Controlled-Release PTH Compound | PTH1R, CALCA, CALCR | PRMT3 4723/4885CARM1 4598/4885PRMT6 4718/4885 |
| US-20230218722-A1 | PTH Compounds with Low Peak-To-Trough Ratios | PTH1R, PTMS, FGF23 | PRMT3 4559/4885CARM1 4870/4885PRMT6 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.